Derek Jonker

基本信息

Career Trajectory

Bio

His greatest work-life pleasure has been working alongside Chris O’Callaghan and so many other amazing people as the chair of the Canadian Cancer Trials Group’s GI Disease Site Committee. Dr. Jonker is married with four adult children. He enjoys wilderness hiking and canoeing, as well as making music with friends and family.

Research Interests

Papers共 345 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Figure 4 from Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

Tharani Krishnan,Joao Paulo Solar Vasconcelos,Emma Titmuss,Robert J. Vanner,David F. Schaeffer,Aly Karsan,Howard Lim,Cheryl Ho,Sharlene Gill,Stephen Yip, Stephen K. Chia,Hagen F. Kennecke,Derek J. Jonker,Eric X. Chen,Daniel J. Renouf,Chris J. O’Callaghan,Jonathan M. Loree

crossref（2025）

Cited0Views0Bibtex

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials

Danielle Lilly Nicholls, Maria C Xu, Luna Zhan, Divya Sharma, Katrina Hueniken, Kaitlyn Chiasson, Mary Wahba,M Catherine Brown,Benjamin Grant,Jeremy Shapiro, Christos S Karapetis,John Simes,Derek Jonker,Dongsheng Tu,Christopher O'Callaghan, Eric Chen,Geoffrey Liu

JCO clinical cancer informatics (2025): e2400114-e2400114

Cited0Views0WOSBibtex

Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

crossref（2025）

Cited0Views0Bibtex

Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

crossref（2025）

Cited0Views0Bibtex

Tumour-free Ctdna Detection As a Decision Tool to Support Organ Preservation in Node-Negative Rectal Cancer Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CCTG CO.28)

Jonathan M. Loree,Emma Titmuss,Carl J. Brown,Thereasa A. Rich,Dongsheng Tu,Derek J. Jonker,Christopher J. O'Callaghan,Hagen Fritz Kennecke

Journal of Clinical Oncologyno. 4_suppl (2025): 20-20

Cited0Views0Bibtex

Figure 3 from Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

crossref（2025）

Cited0Views0Bibtex

Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer: a Multi-Centre, Non-Blinded, Open-Label Phase II Basket Trial

Abha A. Gupta,Anna Tinker,Derek Jonker, Rahma Jamal,Hal Hirte, Eric W. Winquist,Quincy Chu,Christian Kollmannsberger,Ralph Wong,Thierry Alcindor,Torsten O. Nielsen,Ming Tsao,Tricia R. Cottrell,Diane Provencher,John Hilton,Monika K. Krzyżanowska,Christine Elser,Sebastien Hotte,Joana Sederias,Siwei Zhang

eClinicalMedicine (2025): 102991

Cited0Views0WOSBibtex

Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

crossref（2025）

Cited0Views0Bibtex

Clonal Hematopoiesis of Indeterminate Potential and Its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

CANCER RESEARCH COMMUNICATIONSno. 1 (2025): 66-73

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Medical Oncologist

Papers共 345 篇Author StatisticsCo-AuthorSimilar Experts